Task: Fact Verification
Input (English): Paragraph: There is no mention of costs in the story. Although pridopidine is an experimental drug, it may have been useful for the reader to know whether pridopidine could be at least a cheaper alternative to tetrabenazine, the only drug currently approved for Huntington’s disease. The story did not detail the potential benefits of pridopidine. Specifically, how did the patients improve their motor function? The only number provided was that 70% of patients improved. We need to know how this function was measured and to what degree they improved (it is not clear whether the story was talking about statistical significance or clinical significance). The story notes, “Side effects among patients taking the drug were similar to the placebo group.” Dr. Alessandro Di Rocco also agrees with this statement, since the “compound is apparently well tolerated without significant side effects.” However, the story could have been more thorough in letting the reader know exactly what those side effects are. The story makes contradictory statements on the study’s results. At one point, the article reports, “…the drug showed a significant benefit,” while further down in the article, Dr. Alessandro Di Rocco is quoted as saying, “the benefit is modest and limited to the motor symptoms of the disease.” The story could have expanded on Di Rocco’s comment and also could have included some of the study’s limitations. For example, the researchers could not prove their primary hypothesis, for which they wrote in The Lancet: “This study did not provide evidence of efficacy.” The apparent benefits came from the tertiary endpoint, which merits a more cautious interpretation of the results. There is not any disease mongering, but the article does not provide much background information on Huntington’s disease, regarding its epidemiology, risk factors and treatments. However, the story does mention dopamine and its role in movement and coordination. Dr. Alessandro Di Rocco from NYU Langone Medical Center is used as an independent source. The story also adds that the study was funded by European pharmaceuticals company NeuroSearch A/S. The article mentions tetrabenazine – the only drug on the market for Huntington’s disease – and adds that it can “cause serious side effects.” The story mentions that study results are from a phase III clinical trial, but it does not clearly comment on the availability of pridopidine, or the class of dopidine drugs in general. The story could have simply said that this drug is investigational and is not available yet. Pridopidine is an experimental drug candidate for Huntington’s disease and has been in clinical trials for the past several years. The same quotation in the news release is used in the HealthDay story, suggesting that the article was somewhat based off the news release. However, there is some evidence of original reporting, with the inclusion of Dr. Alessandro Di Rocco’s comments. Claim: New Drug Shows Promise Against Huntington’s Disease
Output (English): 1